Further studies exploring the development of CD8+ TEX in the context of BC neoadjuvant chemotherapy and adjuvant therapy regimens may reveal mechanisms for the survival characteristic differences between patients with ER+ BC and TNBC. Here, CD8A is linked to breast cancer.